. 

Based on the recent earnings call, it is recommended to take a cautious or skeptical stance on investing in the company. While the company has presented positive data on their products and potential opportunities, it is important to note that the market for these products is highly competitive with multiple existing treatments and other pharmaceutical companies in the same space. Additionally, there are safety concerns with some of the products, such as an increased risk of inflammation and vitreous hemorrhage with EYLEA in diabetic retinopathy. The company also has a relatively long development timeline for their products, and the potential for significant growth and market uptake could be slower than anticipated. It is important to carefully assess the company's ability to compete in the market and bring their products to market successfully before considering an investment.